PH12021550883A1 - Crystalline salts of a plasma kallikrein inhibitor - Google Patents

Crystalline salts of a plasma kallikrein inhibitor

Info

Publication number
PH12021550883A1
PH12021550883A1 PH12021550883A PH12021550883A PH12021550883A1 PH 12021550883 A1 PH12021550883 A1 PH 12021550883A1 PH 12021550883 A PH12021550883 A PH 12021550883A PH 12021550883 A PH12021550883 A PH 12021550883A PH 12021550883 A1 PH12021550883 A1 PH 12021550883A1
Authority
PH
Philippines
Prior art keywords
crystalline salts
plasma kallikrein
kallikrein inhibitor
crystalline
salts
Prior art date
Application number
PH12021550883A
Other languages
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12021550883(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PH12021550883A1 publication Critical patent/PH12021550883A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PH12021550883A 2018-11-02 2021-04-21 Crystalline salts of a plasma kallikrein inhibitor PH12021550883A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02
PCT/US2019/059385 WO2020092898A1 (en) 2018-11-02 2019-11-01 Crystalline salts of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
PH12021550883A1 true PH12021550883A1 (en) 2022-02-21

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550883A PH12021550883A1 (en) 2018-11-02 2021-04-21 Crystalline salts of a plasma kallikrein inhibitor

Country Status (22)

Country Link
US (11) US10662160B1 (https=)
EP (1) EP3873463A4 (https=)
JP (2) JP2022505670A (https=)
KR (1) KR102810837B1 (https=)
CN (1) CN112969458A (https=)
AR (1) AR116951A1 (https=)
AU (1) AU2019374115B8 (https=)
BR (1) BR112021008249A2 (https=)
CA (1) CA3117123A1 (https=)
CL (1) CL2021001094A1 (https=)
CO (1) CO2021007172A2 (https=)
EA (1) EA202191192A1 (https=)
IL (2) IL322896A (https=)
MA (1) MA54087A (https=)
MX (1) MX2021004917A (https=)
PE (1) PE20211280A1 (https=)
PH (1) PH12021550883A1 (https=)
PY (1) PY1991831A (https=)
SG (1) SG11202103804TA (https=)
TW (1) TW202031255A (https=)
UY (1) UY38438A (https=)
WO (1) WO2020092898A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
BRPI0519331A2 (pt) 2004-12-15 2009-01-20 Bristol Myers Squibb Co formas cristalina de um inibidor de fator xa
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
RU2585683C2 (ru) * 2010-05-19 2016-06-10 Сандоз Аг Очистка позаконазола и промежуточных продуктов для синтеза позаконазола
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
KR102736869B1 (ko) * 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
DK4019022T3 (en) 2015-10-01 2024-02-19 Biocryst Pharm Inc Human plasma kallikrein inhibitors
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成

Also Published As

Publication number Publication date
CN112969458A (zh) 2021-06-15
US20250388548A1 (en) 2025-12-25
UY38438A (es) 2020-05-29
US11618733B2 (en) 2023-04-04
AR116951A1 (es) 2021-06-30
PY1991831A (es) 2020-07-03
US20250388546A1 (en) 2025-12-25
US12545646B2 (en) 2026-02-10
US20250376448A1 (en) 2025-12-11
US11117867B2 (en) 2021-09-14
US20250388545A1 (en) 2025-12-25
IL322896A (en) 2025-10-01
MX2021004917A (es) 2021-06-18
JP2022505670A (ja) 2022-01-14
MA54087A (fr) 2022-02-09
US12590069B2 (en) 2026-03-31
TW202031255A (zh) 2020-09-01
WO2020092898A1 (en) 2020-05-07
US12545647B2 (en) 2026-02-10
BR112021008249A2 (pt) 2021-08-03
EP3873463A4 (en) 2022-06-22
AU2019374115B8 (en) 2025-08-07
US20240109844A1 (en) 2024-04-04
US12590068B2 (en) 2026-03-31
PE20211280A1 (es) 2021-07-19
AU2019374115B1 (en) 2025-07-17
KR20210087037A (ko) 2021-07-09
IL282454A (en) 2021-06-30
US12552750B2 (en) 2026-02-17
KR102810837B1 (ko) 2025-05-20
CO2021007172A2 (es) 2021-06-10
AU2019374115A1 (en) 2021-06-03
US20250388547A1 (en) 2025-12-25
SG11202103804TA (en) 2021-05-28
CA3117123A1 (en) 2020-05-07
EP3873463A1 (en) 2021-09-08
US20200308118A1 (en) 2020-10-01
US20220204454A1 (en) 2022-06-30
JP2024109860A (ja) 2024-08-14
US20200140389A1 (en) 2020-05-07
US20250376447A1 (en) 2025-12-11
US12344585B2 (en) 2025-07-01
EA202191192A1 (ru) 2021-09-23
US20250388549A1 (en) 2025-12-25
US12545645B2 (en) 2026-02-10
US10662160B1 (en) 2020-05-26
CL2021001094A1 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
ZA202202097B (en) Amino pyrimidine ssao inhibitors
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
ZA202206923B (en) New methylquinazolinone derivatives
PH12020550792A1 (en) Compounds useful for inhibiting cdk7
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
AU2018271990A1 (en) Covalent inhibitors of KRAS
EA202193015A1 (ru) Ингибиторы cdk
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
CA2983481A1 (en) Janus kinase inhibitor
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
NZ762034A (en) Human plasma kallikrein inhibitors
MX2020005484A (es) Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2021007247A (es) Derivados de rapamicina.
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
WO2018125880A8 (en) Nrf2 activator
MY193239A (en) Novel b-lactamase inhibitors
MX379576B (es) Derivados de azetidina
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
PH12021550323A1 (en) Dendrimer formulations
ZA201904033B (en) Pharmaceutical compounds